Infectious Disease Treatment Market By Therapeutics (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs, Antiparasitic Drugs, Projected Sales Of Phase Iii Drugs Estimated Till 2025, Tabular Representation Of Phase Ii And I Drugs), By Application (Acquired Immune Deficiency Syndrome (AIDS), Hepatitis B, Hepatitis C, Human Papillomavirus And Other ) - Growth, Future Prospects And Competitive Analysis 2017 – 2025

This report on global infectious disease treatment market studies the increasing demand for infectious disease treatment due to rise in the drug resistant bacterial strain, early disease diagnosis and treatment and promising drug pipeline.

For the purpose of this study, the infectious disease treatment market is segmented into therapeutics (Antibacterial drugs, Antiviral drugs, Antifungal drugs, Antiparasitic drugs) and application type (AIDS, Hepatitis B, Hepatitis C, HPV, MRSA, CT/NG and Others); Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The pipeline analysis for global infectious disease treatment market comprises projected market sales of Phase III anti-infective drugs estimated till 2025. We have estimated sales of very specific molecules based on the type (Imipenem/Cilastatin+relebactum, (MK-7655), S-033188, Cadazolid, Baxdela (Delafloxacin), GS-9620 (TLR-7 agonist), Doravirine (MK-1439), ZERBAXA (MK-7625A)), are the drugs in the pipeline which are anticipated to be launched during the forecast period.

The geographic segmentation of the global infectious disease treatment market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

For the purpose of this study, the global infectious disease treatment market is categorized into:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

North America was observed as the largest market for infectious disease treatment in the base year 2016. According to Centre for Disease Control and Prevention in 2015 about 39,513 new cases of human acquired immune deficiency syndrome (HIV). The growth is attributed mainly due to increasing prevalence of infectious disease, public awareness and early disease diagnosis and supportive reimbursement policies. Europe is expected to be the second largest market due to rising public awareness related with early disease diagnosis, improved healthcare infrastructure, government and non-government organizations arranging awareness activities and camps. 

Growth of Asia Pacific for infectious disease treatment market is attributed by factors like rising prevalence of infectious disease, increasing investments in drug R&D and higher disposable income in these regions. However, factors such as developing health infrastructure, increasing awareness among people about health care and tapping potential market in the remote areas to fuel the rapid growth of infectious disease treatment market in Latin America and Middle East and Africa region in the near future.